NASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $68.10 -3.87 (-5.37%) Closing price 03:59 PM EasternExtended Trading$68.12 +0.02 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Disc Medicine Stock (NASDAQ:IRON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Disc Medicine alerts:Sign Up Key Stats Today's Range$67.00▼$72.3850-Day Range$58.17▼$71.9752-Week Range$40.00▼$99.50Volume636,526 shsAverage Volume464,525 shsMarket Capitalization$2.60 billionP/E RatioN/ADividend YieldN/APrice Target$105.30Consensus RatingModerate Buy Company Overview Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins. Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.AI Generated. May Contain Errors. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 39% of companies evaluated by MarketBeat, and ranked 734th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDisc Medicine has a consensus price target of $105.30, representing about 53.4% upside from its current price of $68.65.Amount of Analyst CoverageDisc Medicine has only been the subject of 2 research reports in the past 90 days.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($6.78) to ($7.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.43% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 10.55, which indicates bearish sentiment.Change versus previous monthShort interest in Disc Medicine has recently increased by 2.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentDisc Medicine has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Disc Medicine this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,327,321.00 in company stock.Percentage Held by Insiders3.76% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRON Stock News HeadlinesDisc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO ...4 hours ago | markets.businessinsider.comDisc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2 at 8:00 AM | globenewswire.comOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.June 2 at 1:00 AM | Behind the Markets (Ad)How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria PatientsJune 2 at 7:18 AM | finance.yahoo.comDisc Medicine Launches Expanded Access Program for Bitopertin for EPP PatientsJune 1 at 8:30 AM | globenewswire.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONMay 28, 2026 | prnewswire.comIRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsMay 25, 2026 | globenewswire.comIRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsMay 19, 2026 | globenewswire.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $79.41 at the beginning of 2026. Since then, IRON shares have decreased by 13.5% and is now trading at $68.65. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by $0.03. When did Disc Medicine IPO? Disc Medicine (IRON) raised $105 million in an initial public offering (IPO) on Wednesday, August 12th 2020. The company issued 10,500,000 shares at a price of $10.00 per share. Who are Disc Medicine's major shareholders? Top institutional shareholders of Disc Medicine include Jennison Associates LLC (1.60%), Assenagon Asset Management S.A. (1.43%), Dimensional Fund Advisors LP (1.03%) and Pictet Asset Management Holding SA (1.01%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, John D Quisel, Mona Ashiya, Pamela Stephenson, William Jacob Savage, Jean M Franchi, Jonathan Yen-Wen Yu, Rahul Khara, Kevin Bitterman, Brian Richard Macdonald, Joanne Bryce and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings5/05/2026Today6/02/2026Jefferies Global Healthcare Conference 20266/03/2026Study update6/15/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IRON's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Disc Medicine$105.30 High Price Target$153.00 Low Price Target$79.00 Potential Upside/Downside+54.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($6.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.94% Return on Assets-33.88% Debt Debt-to-Equity Ratio0.04 Current Ratio24.00 Quick Ratio24.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.52 per share Price / Book3.50Miscellaneous Outstanding Shares38,160,000Free Float36,725,000Market Cap$2.61 billion OptionableNot Optionable Beta0.93 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IRON) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our Partners“How Do Capital Gains Taxes Apply When I Sell My $1.4M Home?” Ask a Pro. Take Advisor Matching Quiz.With estate tax thresholds set to decrease in 2026, a family trust could help lock in current exemptions while...SmartAsset | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredBNZI posted 169 percent revenue growth - is a turnaround formingBanzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredFree: The Crypto Summit That Could Change Your LifeWe have assembled 27 of the top crypto experts in the world. Multi-millionaires, fund managers, coin creato...Crypto 101 Media | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
